XPC gene polymorphisms and breast cancer susceptibility: appraisal of a recent meta-analysis

2011 ◽  
Vol 129 (1) ◽  
pp. 277-279 ◽  
Author(s):  
Fang Wang ◽  
Yan-Feng Zou ◽  
Guo-Ping Sun
Keyword(s):  
Breast Cancer ◽  
Gene Polymorphisms ◽  
Cancer Susceptibility ◽  
Meta Analysis ◽  
Breast Cancer Susceptibility

Five MDM4 gene polymorphisms on cancer risk: An updated systematic review and meta-analysis

2021 ◽  
Vol 36 (2) ◽  
pp. 172460082110338
Author(s):  
Yaxuan Wang ◽  
Zhan Yang ◽  
Xueliang Chang ◽  
Jingdong Li ◽  
Zhenwei Han
Keyword(s):  
Breast Cancer ◽  
Cancer Risk ◽  
Gene Polymorphisms ◽  
Cancer Susceptibility ◽  
Meta Analysis ◽  
Asian Population ◽  
Breast Cancer Susceptibility ◽  
Candidate Gene Studies ◽  
Stratified Analysis ◽  
Risk Of Cancer

Purpose The study aims to provide a comprehensive account of the association of five MDM4 gene polymorphisms (rs1380576, rs1563828, rs10900598, rs11801299, and rs4245739) with susceptibility to cancer. Methods A literature search for eligible candidate gene studies published before 27 February 2021 was conducted in PubMed, Medline and Web of Science. The following combinations of main keywords were used: (MDM4 OR MDMX OR HDMX OR mouse double minute 4 homolog) AND (polymorphism OR mutation OR variation OR SNP OR genotype) AND (cancer OR tumor OR neoplasm OR malignancy OR carcinoma OR adenocarcinoma). Potential sources of heterogeneity were sought out via meta-regression, subgroup and sensitivity analysis. Results Overall, a total of 15 articles with 21,365 cases and 29,280 controls for five polymorphisms of the MDM4 gene were enrolled. In the stratified analysis of rs1380576, we found that Asians might have less susceptibility to cancer. We found that rs4245739 was correlated with a decreased risk of cancer for Asians and breast cancer susceptibility. However, for other polymorphisms, the results showed no significant association with cancer risk. Conclusion MDM4 rs1380576 polymorphism is negatively associated with the risk of cancer in the Asian population. MDM4 rs4245739 polymorphism is inversely associated with cancer risk for Asians and breast cancer susceptibility.

Cytokine Gene Polymorphisms and Breast Cancer Susceptibility

2006 ◽  
Vol 1089 (1) ◽  
pp. 104-109 ◽  
Author(s):  
L. SCOLA ◽  
M. VAGLICA ◽  
A. CRIVELLO ◽  
L. PALMERI ◽  
G. I. FORTE ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Polymorphisms ◽  
Cancer Susceptibility ◽  
Breast Cancer Susceptibility ◽  
Cytokine Gene ◽  
Cytokine Gene Polymorphisms

XRCC3 5′-UTR and IVS5-14 polymorphisms and breast cancer susceptibility: a meta-analysis

2010 ◽  
Vol 122 (2) ◽  
pp. 489-493 ◽  
Author(s):  
Li-Xin Qiu ◽  
Chen Mao ◽  
Lei Yao ◽  
Ke-Da Yu ◽  
Ping Zhan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Susceptibility ◽  
Meta Analysis ◽  
Breast Cancer Susceptibility

scholarly journals Correlations of EZH2 and SMYD3 gene polymorphisms with breast cancer susceptibility and prognosis

2018 ◽  
Vol 38 (1) ◽  
Author(s):  
Shao-Jun Ma ◽  
Yan-Mei Liu ◽  
Yue-Lang Zhang ◽  
Ming-Wei Chen ◽  
Wei Cao
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Gene Polymorphisms ◽  
Tandem Repeats ◽  
Cancer Susceptibility ◽  
Menopausal Status ◽  
Breast Cancer Susceptibility ◽  
Clinical Staging ◽  
Her2 Status ◽  
Cancer Tissues

The aim of the present study was to investigate the correlation of enhancer of Zeste homolog 2 (EZH2) and SET and MYND domain containing 3 (SMYD3) gene polymorphisms with breast cancer susceptibility and prognosis. A total of 712 patients with breast cancer and 783 healthy individuals were selected. Normal breast epithelial cells MCF-10A and breast cancer cells MCF-7, MDA-MB-231, T47D, and Bcap-37 were cultured. Polymerase chain reaction (PCR)-restriction fragment length polymorphism method was applied for genotyping. Reverse-transcription quantitative PCR (RT-qPCR) and Western blotting were used to examine EZH2 and SMYD3 expression in breast cancer tissues and cells. The risk factors and prognostic factors for breast cancer were estimated. The C allele of EZH2 rs12670401 (odds ratio (OR) =1.255, 95% confidence interval (95% CI): 1.085–1.452), T allele of EZH2 rs6464926 (OR =1.240, 95% CI: 1.071–1.435), and three alleles of SMYD3 variable number of tandem repeats (VNTRs) (OR =1.305, 95% CI: 1.097–1.552) could increase susceptibility to breast cancer. Combined genotypes of EZH2 rs12670401 (TC + CC) and EZH2 rs6464926 (CT + TT) were associated with breast cancer susceptibility. Breast cancer tissues had higher EZH2 and SMYD3 expression. EZH2 rs12670401, EZH2 rs6464926, age of menarche, and menopausal status were associated with breast cancer susceptibility. Patients with TT genotype of EZH2 rs12670401 or with CC genotype of EZH2 rs6464926 had higher overall survival (OS). EZH2 rs12670401, EZH2 rs6464926, and clinical staging were independent prognostic factors for breast cancer. SMYD3 VNTR polymorphism exhibited no association with susceptibility and prognosis. EZH2 rs12670401 and rs6464926 polymorphisms, EZH2 and SMYD3 expression, clinical staging, lymph node metastasis, human epidermal growth factor receptor-2 (HER2) status, and metastasis may be correlated with breast cancer susceptibility and prognosis.

Sign in / Sign up

Export Citation Format

Share Document